Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPd Maintenance in High-Risk Myeloma
NCT03756896Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- Jan 2019
- Primary completion
- Jun 2025
- Modality
- Reversible Covalent Inhibitors, Irreversible Covalent Inhibitors, Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib, pomalidomide in multiple myeloma (MM), sponsored by Emory University. Started Jan 2019; status: active, not recruiting.
02
Drugs
carfilzomibpomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03756896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03756896.